Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
Hosted on MSN3h
After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...
An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...
The latest edition of STAT’s Health Tech newsletter brings you important dispatches from the J.P. Morgan Health Care ...
Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...
The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...
leadership skills and extensive experience across the interior Eli Cox is a four-year starter at center and right guard with most time spent at the former including 12 starts in 2024 inside ...
Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback